Tara Shah

October 7, 2023

Conference Coverage 2023

Conference Coverage: 2023 Precision Oncology Summit

We are excited to bring the conference coverage/highlights from the highly anticipated “2023 Precision Oncology Summit” that is taking place this weekend in the vibrant city of San Francisco. This important event

Conference Coverage/Lung Cancer

ESMO 2023 Update – KEYNOTE-671

ESMO 2023 Update – KEYNOTE-671: The First Perioperative Immunotherapy Clinical Trial in Non-Small Cell Lung Cancer Improving Overall Survival Author: Lei Deng, MD Assistant Professor/Medical Oncologist Thoracic, Head & Neck Medical Oncology University of Washington/Fred Hutchinson Cancer Center Key Points:

October 23, 2023

KEYNOTE-087: Pembrolizumab Monotherapy for Relapsed/Refractory Classical Hodgkin lymphoma

Opinion

Written by Dr. Chepsy Philip from Believers Church Medical College Hospital, Tiruvalla, Kerala, India KEYNOTE-087 is a multicentre, single-arm, multicohort, nonrandomized, phase 2 study

Antibody Drug Conjugates

Patient Corner

Author: Dr. Arya Mariam Roy from Roswell Park Comprehensive Cancer Center What are antibody drug conjugates (ADCs)? Antibody drug conjugates (ADCs) are newer targeted medicines

Conference 2023/Conference Coverage 2023/Opinion

Updates from ASCO23 – ADAURA Trial Plenary Lecture

Author: Lei Deng, MD PGY-6 Fellow Of Hematology/Oncology – Roswell Park Comprehensive Cancer Center, Buffalo, NY. Incoming Assistant Professor At UW/Fred Hutch, Seattle, WA Live report from ASCO23, Chicago, IL June 4, 2023

by Tara Shah

June 4, 2023

Conference Coverage 2023/Lung Cancer/Opinion

My Take On KEYNOTE-671: ASCO23 June 3, 2023

Author: Lei Deng, MD PGY-6 Fellow of Hematology/Oncology – Roswell Park Comprehensive Cancer Center, Buffalo, NY. Incoming Assistant Professor at UW/Fred Hutch, Seattle, WA Live report from ASCO23, Chicago, IL June 3, 2023 8am